Literature DB >> 9103208

Mutations of the X region of hepatitis B virus and their clinical implications.

T Uchida1, T Saitoh, H Shinzawa.   

Abstract

Nucleotide (nt) sequences of the X region of more than 130 hepatitis B virus (HBV) isolates were determined and derived from patients with a variety of clinical features. Correlation of nt substitutions with clinicopathological characteristics was attempted. The X region (465nt) is crucial for the replication and expression of HBV because the X protein transactivates the HBV genes and this region contains the core promoter, enhancer II, and two direct repeats. There are several mutational hotspots, some of which seem to relate to immunological epitopes of the X protein. Two kinds of mutations which have important clinical significances were found. One is an 8-nt deletion between nt 1770 and 1777, which truncates 20 amino acids from the carboxyl terminus of the X protein. This deletion leads to the suppression of replication and expression of HBV DNA, resulting in immunoserological marker (HBsAg) negativity. This silent HBV infection is responsible for the majority of non-A to non-E hepatitis. The other mutation substituting T for C (nt 1655), T for A (nt 1764) and A for G (nt 1766) seems to relate to fulminant hepatitis. Further sequencing studies and in vitro mutagenesis experiments will clarify the significance of other mutations of the X region.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9103208     DOI: 10.1111/j.1440-1827.1997.tb04479.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  10 in total

1.  Viral replication modulated by synthetic peptide derived from hepatitis B virus X protein.

Authors:  Chang-Zheng Song; Qing-Wei Wang; Chang-Cheng Song; Zeng-Liang Bai
Journal:  World J Gastroenterol       Date:  2004-02-01       Impact factor: 5.742

Review 2.  X region mutations of hepatitis B virus related to clinical severity.

Authors:  Hong Kim; Seoung-Ae Lee; Bum-Joon Kim
Journal:  World J Gastroenterol       Date:  2016-06-28       Impact factor: 5.742

Review 3.  Occult hepatitis B virus infection.

Authors:  Min-Sun Kwak; Yoon Jun Kim
Journal:  World J Hepatol       Date:  2014-12-27

4.  Synergistic effects of A1896, T1653 and T1762/A1764 mutations in genotype c2 hepatitis B virus on development of hepatocellular carcinoma.

Authors:  H Lyu; D Lee; Y-H Chung; J A Kim; J-H Lee; Y-J Jin; W Park; P Mathews; E Jaffee; L Zheng; E Yu; Y J Lee
Journal:  J Viral Hepat       Date:  2012-08-16       Impact factor: 3.728

Review 5.  Role of occult hepatitis B virus infection in chronic hepatitis C.

Authors:  Nicola Coppola; Lorenzo Onorato; Mariantonietta Pisaturo; Margherita Macera; Caterina Sagnelli; Salvatore Martini; Evangelista Sagnelli
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

6.  Influence of hepatitis B virus X and core promoter mutations on hepatocellular carcinoma among patients infected with subgenotype C2.

Authors:  Noboru Shinkai; Yasuhito Tanaka; Kiyoaki Ito; Motokazu Mukaide; Izumi Hasegawa; Yasuhiro Asahina; Namiki Izumi; Hiroshi Yatsuhashi; Etsuro Orito; Takashi Joh; Masashi Mizokami
Journal:  J Clin Microbiol       Date:  2007-07-25       Impact factor: 5.948

7.  Tumor necrosis factor alpha inhibition of hepatitis B virus replication involves disruption of capsid Integrity through activation of NF-kappaB.

Authors:  Michael Biermer; Robyn Puro; Robert J Schneider
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

8.  Past exposure to hepatitis B: a risk factor for increase in mortality?

Authors:  Raxitkumar Jinjuvadia; Suthat Liangpunsakul; Fadi Antaki
Journal:  J Clin Gastroenterol       Date:  2014-03       Impact factor: 3.062

9.  HBV X gene point mutations are associated with the risk of hepatocellular carcinoma: A systematic review and meta-analysis.

Authors:  Yulan Wang; L I Zeng; Weiqing Chen
Journal:  Mol Clin Oncol       Date:  2016-04-05

Review 10.  Update on occult hepatitis B virus infection.

Authors:  Manoochehr Makvandi
Journal:  World J Gastroenterol       Date:  2016-10-21       Impact factor: 5.742

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.